We conducted a study to test the accuracy ofan immediate and delayed off-line technique for measuring nasal nitric oxide (NO) by comparing it with on-line measurements.
Introduction
The presence of endogenous nitric oxide (NO) in the exhaled breath of humans and animals was first reported by Gustafsson et al in 1991. 1 Since then, interest in this topic has increased. It is now known that exhaled NO originates primarily in the upper airways; the lower airways and lungs make only a minor contribution.' NO has several functions. It plays a role in immunity and in the host defense of the upper respiratory systern.l? it is a regulator of ciliary motility in the human sinonasal mucosa. ?" and it is a modulator of pulmonary function. s? NO is also a marker of inflammation. ' The amount of nasal NO output can be altered by some respiratory diseases . For example, output is increased in the presence of allergic rhinitis' :'? and decreased in cystic fibrosis ,II Kartagener's syndrome, " and sinusitis. 13, 14 Therefore, measurement of nasal NO can serve as a noninvasive tool in the diagnosis of sinonasal diseases.
The on-line measurement ofNO requires several pieces of bulky hardware and a dedicated station. To obtain maximum advantage of on-line NO measurements in the clinical setting, the equipment and all its components must be located either in the clinic, which is usually busy and crowded, or in a remote laboratory, which requires that the patient be transferred. The alternative is to collect a sample in the clinic and transfer it to the centrallaboratory for off-line measurement.
In an effort to refine the latter option, we developed a nasal NO collection and transport system that employs special syringes. Our technique was inspired by those that are used for lower-airway sampling'S" and by personal communication (June 2000) with P.G. Djupesland, MD , and A. Qian, MD, following the publication of their abstract.'? Several articles have been written about online NO measurement techniques ,3,15,16,18-21 but published data on off-line methods are limited. The purpose of this article is to describe our validation of an off-line nasal NO measurement technique.
Materials and methods
One of the authors (C.V.)-a 41-year-old male nonsmoker with mild allergic rhinitis-volunteered to act as the subject of this study . Nasal examination revealed that the subject had a mild septal deviation that obstructed less than 25% of the left nasal passage. Skin-prick testing was positi ve for dust mites (Dermatophagoides pteronyssinus) and seasonal allergens (Kentucky bluegrass, orchard grass, and redtop grass). Because the subject's symptoms were mild , he took no medication for his allergic rhinitis during the study period. The subject also experienced a viral infection of the upper respiratory tract during the study, which increased the amount of nasal NO in his exhaled breath.
NO was measured with a rapid-response chemiluminescent analyzer (NOA 280; Sievers Instruments ; Boulder, Colo.). The sampling flow of the analyzer pump was GU NGOR , VURAL 0.2 L/min. A 2-po int calibration was performed daily, first to 0 with air passed through an NO scrubber tube containing KMn0 4 (potass ium permanganate) and activated charcoal, and then with certified standardized NO gas (45 parts per mill ion) for the span (Datex-Ohmeda; Madison, Wis.). The amount of NO in ambient air (baseline) was recorded before each on-line measuremen t.
The NO analyzer signal output was fed into a computer data acqui sition program (NO analys is software for NOA 280, Version 3.00 PNE; Sievers In struments). The program featured a real-time display of NO vs time written directly into the computer' s hard disk as a dat a file. Thi s program plotted NO concentrations against time and printed the results in graph form .
During each measurement, on-and off-line NO samples were taken at a con stant flow of5 L/min. Flow was created by a suction pump, and it was continuously monitored by a highl y accurate flow meter (Aalborg Instruments; Mon sey, N.Y.). Baseline NO conc entration s were subtracted from measured concentrations before any data were analyzed.
A latex nasal oli ve (ENTso l Adapter; Kenwood Th erapeuti cs; Fairfield, N.J. ) was gent ly introduced into the subject's right naris. The olive was connected to a filter (Resp-Ba c; Medicomp; Princ eton, Minn .) and a respirator tube (AirLife; Alle giance Health care; McG aw Park, Ill.) with a gas-sampling connector and midstre am sampling port (Res piratory Support Produ cts; Irvine, Cali f.) (figure 1). Th e subject closed his velum by holding his breath . Room air entered throu gh the left nostril and was aspirated from the right nostril at a con stant rate of 5 L/ min . NO sampling was performed through a side port ju st distal to the tube.
On-line measurements. After 10 to 20 seconds of breath holding, a plateau of NO levels was reached. Extrapolation of the mean by software from this plateau was accepted as the on-line mea sur ement value. For nasal NO measurements , 30 seconds of breath holding is accepted as sufficient to achieve a plateau at a flow bet ween 3.2 and 5.2 L/min,19 a fact that was confirmed in our study.
Off-line measurements. Four off-line samples were taken, beginning 5 to 10 minutes followi ng the on-line measurement and after 20 seconds of breath holding. Sample s were drawn throu gh the side port and captured in four 50-ml syrin ges (adjustable-plunger-sea led gas/liquid syringes ; Glenco; Hou ston). Th e syringes were sealed by closing a microvalve and twisting an adj ustable plun ger , and the samples were kept at room temperature.
The NO content in syringe #1 was mea sured immediately after it was dra wn by connecting the syringe to the analyzer. The samples in syringes #2, #3, and #4 were analyzed 1,2, and 4 hours later, respectively. sta tistical analysis of the result s was performed by correlation analys is and the Bland-Altman test."
Results
All measurements were performed at a flo w rate of 5 L/ min . Results were reported as parts per billion (ppb) in accordance with the recommendation of the American Tho racic Society.IS Correlation s bet ween on-and off-line mea surements (as determined by linear regression analysis) and 95% confidence interv als were depicted in graph form; multiple correlation coefficient (R2) values ranged between 0.95 and 0.98 (figure 2). Bland-Altman plots depicted the difference to mean within 2 standard deviations (SDs) ( figure 3 ). The differences were calculated by subtracting corresponding off-line measurements from on-line measurements. Agreement bet ween datapoints was high, and onl y a few points were beyond the 2-SD threshold in any graph.
Discussion
The equipment currently used to mea sure NO in exhaled or nasal air is not portable , and transporting patients to an analyze r is not always feasible. In certain circumstances (e.g., when patient s are hospitalized or when the distance to the laborato ry makes it impractical to transfer the patient there), a more practic al alterna tive is to store the air samples in suitable cont ainers and carry them to the analyzer for delayed off-line measurement. and transport the samples. Paredi et al did sugges t that there is no change in the NO concentration of samples kept in polyethylene reservoirs for up to 12 hours. To prevent the absorption of NO by water vapor and carbon dioxide ("q uenching") over a 24-hour period, they placed silica gel into the reservoir. The corre lation between on-and off-line measurements in our study was high (95 to 98 %). Therefore, we concl ude that the storage media we used appear to have had a negligible effec t on the chemica l state of the NO-at least overa 4-ho ur period. The syringes used in our study were made of borosilicate glass, and the plungers were made of Teflon; neither of these materials reac ts to most chemicals.
One possible problem with off-line measure ment is diffusio n of NO from or into the reservoir. The rate and directio n of diffusion are related to the integrity of the reservoir's seal and the amount of ambie nt NO. If the concen tration of ambient NO is less than the concentration of NO in the reservoir, diffusion from the reservo ir to the ambient air can be expected. Conversely, if the concentration of ambient NO is greater, one would expec t that the direction of diffusion would be toward the reservoir ; however, such a diffusion is not possible in nasal samples
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..... c 0::;: 10 2:1: because the NO in nasal air is always higher than the NO in ambient air. If the difference between the concentration of ambient NO and reservoir NO is great, the expected rate of diffusion will be high. The nasal air samples we kept in syringes for 4 hours did not undergo any dramatic change in NO concentration. Therefore, we conclude that the seals on our syringes were sufficiently tight to prevent leakage for at least 4 hours. A study to test the airtightness of these seals for longer durations is currentl y under way in our laboratory.
Finally, when performing off-line NO measurements in either a clinical or research setting , it is necessary to know the concentration of ambient NO in the environment in which the samples are taken. Therefore, the clinician or researcher must not neglect to sample the air in the surroundin g environm ent in order to measure its ambient NO content.
Although this study was condu cted with the assistance of only one subject, we tested our system with both low and high concentrations of nasal NO, and in every situation, the off-line measurement proved to be reliable . The results of our method of off-line measurement are repro-ducible and in good agreement with those seen with online measurement. We conclude that immedi ate and delayed off-line measurement s of nasal NO are a practical complement to the on-line method .
The following treatme nt-re lated adverse events were eac h rep orted in a single subject: dermatitis, ecze ma, ery the ma tous rash, follicu lar rash , rash, hypoaesthesia, tinnitus, dyspepsia, hot flu shes, flushing, and otorrhagia.
Sub jects with Oti tis Extern a The following treatmen t-related adverse events occu rred in 1% or more of the su bjec ts wit h intacttympanic membranes. Sub 
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Adve rse Event
Nursing Mothers: In nursing women, a single200 mg oral doseresulted in concentrationsof ofloxacin inmilk which were simi lartothose foundinplasma. It is not knownwhether ofloxac in isexcreted in human milkfollowingtopical oti c adminis tration. Because of thepotential forseriousadverse reactionsfrom ofloxacin in nursing infants, a decision should be madewhetherto discontinue nurs ing or to discontinue the drug , taking into account the importance of the dr ug to the mother. Ped iatr ic Us e: No cha nges in hearing function occurred in 30 pedia tric subjects treated with ofloxacin otic and tested for audiometric parame ters. Although safety and eff icacy have been demonstrated in pediat ric patients one year and older, safety an d effect iveness in infants below the age of one year have not bee n establ ished . Althoug h quino lones , includ ing ofloxacin , have been shown to cause arthropathy in immature animals after systemic administration, young growi ng guinea pigs dose d in the middle ea r with 0.3% ofloxaci n otic so lution for one month showed no syste mic effects , quino lone-ind uced lesions, erosions of the ca rliiage in weightbea ring joints , or othe r signs of ar thropathy. ADVERSE REACTIONS In the Phase III registration trials, a total of 885 subjects were treated with ofloxacin otic solution. This included 229 subjects with otitis externa (with intact tympan ic membranes) and 656 subjects with acute otitis media with tympanostomy tubes or chronic supp urative otitis media with perforated tympanic mem branes. The report ed treatme nt-related adve rse events are listed below: For patie nts 12 years and older: Ten drops (0.5 mL, 1.5 mg otloxacln) inst illed into the affected ear twice da ily for ten days. Th e so lution should be wa rme d by holding the bottle in the hand for one or two minutes to avoid dizz iness which may result from the instillation of a cold so lution. The patient sho uld lie with the affecte d ea r upward, and then the drops sho uld be instilled . T his pos ition should be mai ntained for five minutes to faci litate pe netrat ion of the dro ps into the ea r ca nal. Repeat, if necessary, for the opposite ea r. Acute Otitis Med ia in p edi atric pa ti en ts w it h ty m pa n o s t o my tubes: T he recomm ended dosage regimen for the treatm ent of acute otitis media in pediatric patients (from one to 12 years old) with tympa nostomy tub es is: Five dro ps (0.25 mL, 0.75 mg ofloxac in) instilled into the affected ear twice dai ly for ten days . Th e solution shou ld be wa rmed by holding the bottle in the hand for one or two minutes to avoid dizziness which may result from the instillation of a cold sol ution.The patient should lie wit h the affected ea r upwa rd, and then the drops should be instille d.The tragus shou ld then be pumped 4 times by pushing inward to fac ilitate penetration of the drop s info the middl e ear. This pos ition sho uld be maint ain ed for five minut es. Repeat, if necessary, for the oppos ite ear . Ch ronic Suppurat i ve Ot iti s Me dia wi t h p erforated tymp ani c m embran es : The recommended dosage regimen for the treatment of chro nic supp urative otitis media with perforated tym panic membranes in patients 12 years or olde r is: Ten drops (0.5 mL , 1.5 mg of loxaci n) instilled into th e affected ea r twice da ily for fourtee n days . The so lution shou ld be warme d by holdin g the bottle in the hand for one or two minutes to avoid dizziness which may result from the instillation of a cold solution. The patient sho uld lie with the affected ea r upward, before instilli ng the dro ps. The tragus shou ld the n be pumped 4 times by push ing inward to facilitate pene tration into the middle ea r. This position should be maintained for five minutes. Repeat, if necessary, for the oppos ite ea r. Brief Summary. Please see product insert for comp lete prescribing information.
For otic use only.
INDICATIONS AND USAGE FLOXIN@ Otic (ofloxac in otic so lution) 0.3% is indicate d for the treatme nt of infections caused by susceptible strains of the des ignated microorga nisms in the specific conditions listed below :
Otitis Ext ern a in adults and pediatric patien ts, one year and olde r, due to Staphylococcus aureus and Pseudomonas aeruginosa . The systemic administration of quinolones, including ofloxacin at doses much higher than given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bea ring joints and other signs of arthropathy in immature animals of variousspecies.
Young grow ing guinea pigs dosed in the mid dle ea r with 0.3 % of loxaci n otic solution showed no system ic effec ts, lesion s or erosio ns of the ca rtilage in weig ht-beari ng joi nts , or other signs of arthropathy. No drug-related structural or functional c hanges of the coc hlea and no lesions in the ossic les were noted in the guinea pig following otic adm inistratio n of 0.3% ofloxac in for one month.
No signs of local irritation we re found when 0.3% ofloxaci n was app lied topically in the rabbit eye. O floxac in was also s hown to lack derm al sens itizing po te ntia l in the guinea pig max imizati on study . Information for Pat ient s: Avoid contam inating the applicator tip wit h material from the fingers or othe r so urces. Th is precau tion is necessary if the ster ility of the drops is to be preserved. Syste mic quinolones, includ ing ofloxac in, have been associated with hypersensitivity reactions, eve n followi ng a single dose. Discontinu e use immediately and co ntact you r phys icia n at the first s ign of a rash or allergic reaction . Ot it is Externa Prior to administration of FLOXIN@ O tic in patients wit h otitis externa, the solu tion sho uld be warmed by holding the bottle in the hand for one or two minutes to avoid dizziness which may resu lt from the instillation of a cold so lution.Th e patient shou ld lie with the affec ted ea r upward, an d the n the drops should be instilled. This pos ition shou ld be maintained for five minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the op posite ea r (see DOSAGE AND AD MI NISTRATION). Acute Oti tis Med ia an d Chronic Suppur at iv e Ot iti s Med ia In pediatric patients (fro m 1 to 12 years old) with ac ute otitis me dia wifh tympa nos tomy tubes and in patients with chronic suppura tive otitis media with perforated tympan ic membranes, prio r to administ ration , the sol ution shou ld be wa rmed by holding the bott le in the hand for one or two minutes to avoid dizziness wh ich may result from the instillation of a cold so lution. The patien t sho uld lie wifh the affec ted ea r upward, and then the drops sho uld be inst illed. The tragus shou ld then be pumped 4 tim es by pushing inward to facilitate penetration of the drops into the midd le ear. This position sho uld be maintained for five min utes . Repeat, if necessary, for th e opposite ea r (see DOSAGE AN D AD MI NISTRATION). Drug Interact ions: Spec ific dru g interaction studies have not bee n conducted wit h FLOXI N@ Otic.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term stud ies to dete rmi ne the ca rcinoge nic potential of ofioxacin have not been co ndu cted. Of loxac in was not mufagen ic in the Ames test , the sis te r chro matid exc hange assay (Chinese hamster and human ce ll lines), the unschedul ed DNA sy nthes is (UDS) assay using hum an fibroblasts, the do minan t leth al assay , or the mou se mi cro-n ucleu s assay . Ofloxacin was positive in the rat hepatocyte UDS assay, and in the mouse lymphoma assay. In rats, of loxaci n did not affec t ma le or female reproductive perfo rmance at oral doses up to 360 mgl kgl day. This wo uld be ove r 1000 fimes the maximum recomm end ed clinical dose, based upon body surface area , ass um ing total abso rption of ofloxac in fro m the ea r of a patient treated with FLOXIN@ Otic twice per day. Pregnancy Teratogenic effects : Pregnancy Catego ry C. Ofloxacin has bee n show n to have an emb ryoc ida l effec t in rats at a dose of 8 10 mgl kglday and in rabb its at 160 mglkg lday. These dosages resulted in decreased fetal body we ights and inc rease d fetal mortality in rats and rabb its, respectively. Min or fetal ske letal va riations were reported In rats receiving doses of 810 mgfkgfday. Ofloxac in has not bee n shown fo be teratogenic at doses as high as 8 10 mgfkglday and 160 mglkglday when ad ministe red to preg nant rats and rabbits , respectively. Ofloxac in has not been show n to have any adverse effects on the developing emb ryo or fetus at doses relevant to the amo unt of of loxac in that will be deliver ed ototopically at the recommended c linica l doses. Nonter atogenic EHect s: Ad difio nal stud ies in the rat de monst rate d that doses up to 360 mglkgl day duri ng late ges tafio n had no adverse effects on late fetal develop ment, labor, delivery, lactation, neonatal viab ility, or growt h of the newborn . There are, howeve r, no adequate and well-controlled studies in preg na nt wome n. FLOXIN@ Otic should be used du ring pregnan cy only if the po tential ben efit ju stifi es the pote ntia l risk to the fetus. All rights reserved. 
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